Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
NCT02129751Phase 4Not yet recruiting
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jul 2027
- Primary completion
- Jul 2030
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of bupropion in major depressive disorder (MDD), sponsored by Valeant Pharmaceuticals. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02129751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129751.